Celcuity (CELC) Expected to Announce Quarterly Earnings on Wednesday

Celcuity (NASDAQ:CELC) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 14th. Analysts expect Celcuity to post earnings of ($0.85) per share for the quarter.

Celcuity (NASDAQ:CELC) last released its earnings results on Monday, March 31st. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.13). On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Trading Up 3.4 %

Celcuity stock opened at $10.53 on Friday. The company has a 50 day moving average price of $10.11 and a 200 day moving average price of $11.91. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. Celcuity has a 52 week low of $7.58 and a 52 week high of $19.77. The firm has a market capitalization of $398.44 million, a price-to-earnings ratio of -4.03 and a beta of 0.56.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CELC. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price target on shares of Celcuity in a research report on Friday, April 11th. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Celcuity in a report on Tuesday, April 1st. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.